20th September 2019,
Vanessa Selak, Bruce Arroll, Chris Bullen, Rob Doughty, Corina Grey, Matire Harwood, Sue Crengle
Cardiovascular disease (CVD) is one of the major causes of mortality, morbidity and inequities globally. The World Health Organization (WHO)’s action plan to reduce the burden of CVD, as well…
The full contents of this page is only available to subscribers.
To view this content please login or subscribe
Aspirin, statins and blood pressure-lowering medication are recommended for most people who have already had a cardiovascular event (such as a heart attack or stroke) as these medications substantially reduce their risk of having another one. Unfortunately a lot of people are missing out on these medications. One way to improve access to medications is by combining them into a single pill or capsule (a “polypill”). Despite considerable evidence supporting the safety and effectiveness of polypills for people who have already had a cardiovascular event they are not currently funded by PHARMAC.
Wald and Law, who popularised the term ‘polypill’ in 2003, proposed giving everyone above a certain age a polypill to reduce the burden of cardiovascular disease (CVD). A more compelling potential application, proposed in 2001 by the World Health Organization, is to use a polypill containing antiplatelet, statin and blood pressure-lowering therapy among people with established CVD, in whom the components are already indicated but in whom guideline implementation and adherence are suboptimal. This article outlines relevant international and New Zealand evidence on the likely benefits and harms of a polypill for the secondary prevention of CVD. The evidence indicates that the benefits are likely to outweigh the harms, particularly given the persistence of substantial treatment gaps and inequities in the management of and outcomes in CVD. The time is long overdue for the polypill to be funded for the secondary prevention of CVD.
- World Health Organization. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva: World Health Organization, 2013.
- Ministry of Health. Cardiovascular disease risk assessment and management for primary care. Wellington: Ministry of Health 2018.
- Wilson N, Jones AC, Nghiem N, et al Preventing cardiovascular disease in New Zealand: making better use of statins but also tobacco control, changing the food supply and other strategies. NZMJ 2018;131:61-7.
- Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-24.
- World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions - Wellcome Trust meeting report 1-3 August 2001. Geneva: World Health Organization, 2002.
- Ministry of Health. Health loss in New Zealand 1990-2013: A report from the New Zealand Burden of Diseases, Injuries and Risk Factors Study. Wellington: Ministry of Health, 2016.
- Kerr AJ, Broad J, Wells S, et al Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart 2009;95:125-9.
- University of Auckland, Health Quality & Safety Commission. Cardiovascular outcomes Health Quality & Safety Commission Atlas of Healthcare Variation 2012. (accessed 3 December 2012).
- Yusuf S, Islam S, Chow CK, et al Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43.
- Bramley D, Riddell T, Crengle S, et al A call to action on Māori cardiovascular health NZMJ 2004;117:U957.
- Te Rōpū Rangahau Hauora a Eru Pōmare. Mana Whakamārama - equal explanatory power: Māori and non-Māori sample size in national health surveys. Wellington: Ministry of Health, 2002.
- Selak V, Elley C, Crengle S, et al Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials 2011;32:909-15.
- Selak V, Elley C, Bullen C, et al Effect of fixed dose combination therapy on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318.
- Selak V, Harwood M, Elley C, et al Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: Findings from a pragmatic randomised controlled trial. Eur J Prev Cardiol 2016;DOI: 10.1177/2047487316637196
- Webster R, Patel A, Selak V, et al Effectiveness of fixed dose combination medication (‘polypills’) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. Int J Cardiol 2015;205:147-56. doi: http://dx.doi.org/10.1016/j.ijcard.2015.12.015
- Selak V, Webster R, Stepien S, et al Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. Heart 2019;105:42-8.
- Laba T-L, Hayes A, Lo S, et al An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Med J Aust 2014;11:671-3.
- Singh K, Crossan C, Laba T, et al Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol 2018;262:71-8.
- Selak V, Webster R. Polypills for the secondary prevention of cardiovascular disease: effective in improving adherence but are they safe? Ther Adv Drug Saf 2018;9:157-62.
- Selak V, Bullen C, Stepien S, et al Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. Eur J Prev Cardiol 2016;DOI: 10.1177/2047487316638216
- Webster R, Castellano JM, Onuma OK. Putting polypills into practice: challenges and lessons learned. Lancet 2017;389:1066-74.
- PTAC Cardiovascular Subcommittee. Minutes of meeting held 27 September 2017. Available from https://www.pharmac.govt.nz/assets/ptac-cardiovascular-subcommittee-minutes-2017-10.pdf [Accessed 29 July 2019]. Wellington: PHARMAC, 2017.
- Pharmacology and Therapeutics Advisory Committee. Minutes of meeting held 8 and 9 February 2018. Available from https://www.pharmac.govt.nz/assets/ptac-minutes-2018-02.pdf. [Accesssed 29 July 2019]. Wellington: PHARMAC, 2018.
- PTAC Cardiovacular Subcommittee. Minutes of meeting held 8 May 2019. Available from https://www.pharmac.govt.nz/assets/ptac-Cardiovascular-Subcommittee-Minutes-2019-05.pdf [Accessed 29 July 2019]. Wellington: PHARMAC, 2019.
- Roshandel G, Khoshnia M, Poustchi H, et al Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019;394:672-83.
- ST-Elevation Myocardial Infarction Guidelines Group, New Zealand Branch of the Cardiac Society of Australia and New Zealand. ST-elevation myocardial infarction: New Zealand management guidelines, 2013. NZMJ 2013;126:127-64.
- Webster R, Grobbee DE, Rodgers A. The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence. Eur J Prev Cardio 2019:DOI: 10.1177/2047487319872660.
The downloadable PDF version of this article is only available to subscribers.
To view this content please login or subscribe